Wang et al. [348] reported the preparation and evaluation of recombinant human epidermal growth factor (rhEGF) conjugated to methoxy-PEG-propionaldehyde (mPEG-PPA, 5 kDa) for the development of mono-, di- and tri-PEG conjugates for the treatment of stroke-injured brain via an invasive minipump/catheter system [348]. The gene discussed is EGF; the disease is stroke disorder.